MREO - Mereo Biopharma stock rises as alvelestat high dose shows promise in lung disease in phase 2 trial

Mereo BioPharma (NASDAQ:MREO) reported results from a mid-stage study of its oral drug alvelestat to treat a lung condition. The phase 2 trial, dubbed ASTRAEUS, evaluated two different doses of alvelestat (high or low dose) or placebo in patients with severe alpha-1 antitrypsin deficiency (AATD)-associated emphysema. A total of 98 patients were dosed in the trial. AATD is is a genetic disorder characterized by low levels of a protein called alpha-1 antitrypsin, which can cause emphysema, a lung condition that causes shortness of breath. In this disorder, air sacs in the lungs are damaged. The company said that at the high dose, alvelestat showed statistically significant changes versus placebo in all three primary biomarker endpoints. "We look forward to analyzing the additional data on the secondary and exploratory endpoints and to engaging with the regulators on the design of a pivotal study," said Mereo CEO Denise Scots-Knight. Mereo said that statistically significant inhibition of

For further details see:

Mereo Biopharma stock rises as alvelestat high dose shows promise in lung disease in phase 2 trial